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ABSTRACT
As numerous bodies of research have characterized the adipocytokine adiponectin
(ACRP30) as an anti-diabetic compound, this work serves as an analysis to partly elucidate the
potential usage of supplementary adiponectin as a therapeutic compound in the treatment of type
II diabetes mellitus. In this work, a meta-analysis was conducted to centralize large amounts of
data on adiponectin’s insulin sensitizing characteristics in conjunction with like-minded studies
utilizing metformin treatment as the diabetic standard of care. Upon comparison of fasting
glucose, fasting insulin, and glucose tolerance test area under the curve reduction percentages, it
is quite clear that ACRP30 has significant insulin enhancing properties in mouse models rivaling
SOC metformin. Yet, inconsistent dosing comparisons in this analysis, the unknowns of chronic
hyperadiponectinemia in humans, as well as variations in age of human diabetic patients warrant
further standardized research to suggest that adiponectin supplementation can rival that of
modern-day standard of care for type II diabetes mellitus.
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INTRODUCTION
Diabetes Mellitus is a group of metabolic diseases characterized by chronic
hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Among this
group are autoimmune type 1 diabetes, monogenic diabetes, type 2 diabetes (NIDDM), latent
autoimmune diabetes in adults, and gestational diabetes (Kharroubi, A. T., & Darwish, H. M.,
2015). According to the latest National Diabetes Statistics Report by the Center for Disease
Control (CDC), diabetes has been quantified in an alarming 10.5% of the US population (CDC,
2020). Type 2 diabetes is the most prevalent classification of diabetes among adults worldwide
(Kharroubi, A. T., & Darwish, H. M., 2015). With the upward trend witnessed in the CDC
report, potential ameliorations should be at the forefront of research. Type 2 diabetes typically
arises due to a combination of a sedentary lifestyle, obesity, poor diet, smoking, significant
alcohol consumption, and the supported presence of known pro-diabetic genes (Olokoba, A. B.,
Obateru, O. A., & Olokoba, L. B., 2012). Multiple therapeutics exist, yet the therapeutic control
of glycemia can still fail. (Achari, A. E., & Jain, S. K., 2017). Many therapeutics exist such as
Metformin, Glimepiride, Voglibose, Sitagliptin, thiazolidinediones, and Gliflozin category drugs
(Banerjee et al. 2019). Yet, each of these possible therapeutics expect the possibility of quite
negative side effects along with the potential of failed treatment (Banerjee et al. 2019).
While environmental factors are important in diagnosis, diabetes has been shown to have
a genetic component regarding its prevalence in the global population. More specifically, while
genetics influences both classifications, type II diabetes mellitus has a stronger genetic
association than type I diabetes. Individuals with one type II diabetic parent have a 40% chance
of developing the disease while those with two diabetic parents have a 70% chance of
8

developing diabetes in their lifetime (Ali, O., 2013). In addition, this heritability variates with
respect to imprinting as the risk of type II diabetes mellitus is higher if the patient’s mother is
diabetic when in comparison to those with diabetic fathers (Lyssenko, V., et al., 2015).
Adipokines are a group of signaling proteins acting as the endocrine mediator of adipose
tissue cells, the importance of which are becoming readily apparent with increasing research
(Kwoon, H., & Pessin, J., 2013). The adipocytokine adiponectin (ACRP30) has emerged as a
potential amelioration for type II diabetes as insulin resistance is combated in contrast to absolute
insulin deficiency as seen in Type I diabetes. Exogenous adiponectin supplementation in humans
and rodents has shown insulin-sensitizing, anti-inflammatory, and anti-atherogenic
characteristics (Achari, A. E., & Jain, S. K., 2017). According to Lebovitz, “Insulin resistance is
defined clinically as the inability of a known quantity of exogenous or endogenous insulin to
increase glucose uptake and utilization in an individual as much as it does in the normal
population.” The body, through the negative effects of lipid accumulation, inflammation, and
metabolic overload, has come to have a decreased response to insulin referred to as insulin
resistance (Maahs, D. M., West, N. A., Lawrence, J. M., & Mayer-Davis, E. J. 2010 and Muoio,
D., Newgard, C. (2008). To combat diabetes and help control glucose levels, increasing the
body’s sensitivity to insulin is paramount from a treatment standpoint (Achari, A. E., & Jain, S.
K., 2017).
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REVIEW OF THE LITERATURE
Definition and Presentation of Type II Diabetes Mellitus
Diabetes Mellitus is a group of metabolic diseases with the presentation of persistent
hyperglycemia and metabolic abnormalities secondary to the inadequacy of the availability or
body’s sensitivity to insulin (Kharroubi, A. T., & Darwish, H. M., 2015). More than 90-95% of
diabetics have the Type II classification (Kharroubi, A. T., & Darwish, H. M., 2015). Insulin
resistance is held as the primary accountable construct for the onset of Type II diabetes mellitus.
This resistance in type II, non-insulin dependent diabetes mellitus (NIDDM), patients increases
the total demand for insulin required for physiological glucose uptake. Insulin production
increases initially to meet increasing demand, yet, over time, production decreases as pancreatic
β cells undergo change trying to keep up with supraphysiological demand (Goyal, R., & Jialal I.,
2021). In fact, β cell mass and function in type II diabetics is significantly decreased over time
which can eventually lead to patient dependency on exogenous insulin (Sakuraba, H., et al.,
2002). Yet, unlike other categories of diabetes, NIDDM patients do not have to be dependent on
insulin (Kharroubi, A. T., & Darwish, H. M., 2015).
Type II diabetes is most prevalent in individuals over 45 years old with a recent upward
trend in children and young adults. This has been attributed to the increasing prevalence of
sedentary lifestyles, obesity, and high fat diets. In fact, most patients with NIDDM are obese or
possess a high percentage of body fat (Goyal, R., & Jialal I., 2021). While previously stated,
though a large portion of diabetes presentation is due to environmental and lifestyle factors,
genetic heritability is important to consider in the process of screening and potential diagnosis of
diabetes mellitus (Lyssenko, V., et al., 2015).
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The presentation of type II diabetes mellitus includes polydipsia, polyuria, fatigue, and
the slow healing of wounds (Goyal, R., & Jialal I., 2021). Initial presentation of slight
hyperglycemia can become severe due to infection or stress. This severe hyperglycemia can lead
to a presentation of ketoacidosis or nonketotic hyperosmolar syndrome in these diabetic patients
(Goyal, R., & Jialal I., 2021).
It is important to recognize in this discussion that while insulin resistance is a defining
trait of type II diabetes, not all patients with insulin resistance are type II diabetic. Therefore, a
general knowledge of diagnostic criteria is paramount.
Diabetes Diagnosis
Chronic hyperglycemia is key for the diagnosis of NIDDM (Seino, Y., et al., 2010).
Diabetes diagnosis requires one of the following in patient presentation: a fasting glucose ≥126
mg/dl, a two-hour post 75 gram oral glucose tolerance test (OGTT) ≥200 mg/dl, or a nonfasting
casual glucose of ≥200 mg/dl (Seino, Y., Nanjo, K., Tajima, N. et al., 2010).
Mechanisms of Insulin Resistance
Generally, aberrations in insulin receptor substrate one (IRS-1) and insulin receptor
substrate two (IRS-2) pathways have been heavily explored as to their contribution to the
development of insulin resistance (Kharroubi, A. T., & Darwish, H. M., 2015). IRS proteins
seem to be cornerstone to intracellular insulin response. Decreased levels of these IRS signaling
proteins have been implicated in the attribution of insulin resistance in both rodents and humans
(Kwon, H., & Pessin, J. E., 2013). Abnormalities in IRS signaling can arise from aberrant
phosphorylation of Protein Kinase B (AKT) and Protein Kinase C (PKC) (Muoio, D., Newgard,
C., 2008). Notably, AMP-activated protein kinase, c-Jun N-terminal protein kinase, as well as G11

Protein coupled receptor (GPCR) kinase 2 are not dependent on insulin but have been shown to
inappropriately phosphorylate substrates in the insulin pathway in an insulin resistant state
(Muoio, D., Newgard, C., 2008).
As a whole, elevated free fatty acid levels in plasma are associated with decreased insulin
sensitivity (Satoh, H. et al., 2005). Plasma nonesterified fatty acids (FFA) have been identified as
the primary vehicle for lipid circulation in plasma (Satoh, H. et al., 2005). The primary source of
fatty acid liberation into plasma is directly from adipose tissue. Since it is well accepted that high
levels of free fatty acids in the bloodstream lead to adverse metabolic complications, it is feasible
that increasing levels of adipocytes and the associated circulation of lipids may lead to the
development of insulin resistance (Satoh, H. et al., 2005). In the liver, insulin resistance is
thought to be secondary to the gathering of fatty acids due to a deficiency in their oxidation and
breakdown (Muoio, D., Newgard, C., 2008). Intracellularly, with excesses of FFAs, normal
oxidation cannot be properly performed, resulting in the abnormal conversion of these fats into
diacylglycerols, triglycerides, and ceramides, the presence of which positively correlate to
insulin resistance through interaction with insulin signaling kinases (Muoio, D., Newgard, C.,
2008). In muscle tissue, similar theories are seen wherein levels of fatty acids and their
peroxidative by-products are strongly correlated to insulin resistance (Muoio, D., Newgard, C.,
2008, and Shulman, G. I., 2000).
Clearly, increasing concentrations of fatty acids both intracellularly and in circulation are
directly correlated with insulin resistance. Other theories exist that this intramuscular insulin
resistance can result from by-products of inappropriate lipid oxidation and lipid accumulation in
the mitochondria (Muoio, D., Newgard, C., 2008). In addition, it has been suggested that
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impairment of metabolic flexibility, the capacity to adapt substrate oxidation rates in response to
changes in fuel availability, is a key indicator and contributor to insulin resistance (Shulman, G.
I., 2000, and Rynders, C. A., Blanc, S., Dejong, N., Bessesen, D. H., & Bergouignan, A., 2017).
Clearly, a whole-body approach to metabolism is necessary to fully elucidate its contribution to
insulin resistance. It is quite evident that insulin resistance does not arise from a singular cellular
mechanical failure, rather, it is the consequence of multiple aberrations in direct insulin
dependent and non-dependent pathways.
Adipocytes
Previously thought as only a storage cell, adipose tissue has demonstrated importance in
maintaining bodily homeostasis (Rosen, E., & Spiegelman, B., 2006). Adipocytes are clearly
involved in the processes of nutrient homeostasis, immune response, blood pressure regulation
and inflammation. Specifically, it is now clear that adipocytes have an undeniable effect on
glucose homeostasis and must be considered in the treatment of diabetes (Rosen, E., &
Spiegelman, B., 2006). More specifically, adipocytes can control and regulate the homeostasis
and metabolism of fatty acids and sugar through the secretion of adipokines, a group of bioactive
peptides (Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P., 2008). Among these are
leptin, tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), and adiponectin. The majority of
adipokines are pro-inflammatory and positively correlate with adiposity. Other antiinflammatory adipokines such as adiponectin have a negative correlation with adiposity
(Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P., 2008). It has been demonstrated that
visceral and subcutaneous adipose tissue vary in their ability to secrete adipokines thereby
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regulating inflammation and insulin resistance (Guilherme, A., Virbasius, J. V., Puri, V., &
Czech, M. P., 2008).
Adipokines
As the endocrine mediator of adipose tissue, the effects of adipokines (adipocytokines)
are incredibly diverse (Kwon, H., & Pessin, J. E., 2013). Chemerin is highly expressed in white
adipose tissue and showcases anti-inflammatory effects while also promoting adipocyte
differentiation. While not thoroughly as explored as adiponectin in this work, chemerin has also
been shown to enhance insulin receptor responsiveness. (Satoh, H., et al., 2005). Yet, chemerin
levels have not been shown to be greatly differentiated between human controls and those
individuals with type II diabetes mellitus. Leptin is one of the earliest discovered adipocytokines
and has shown essential activity in the regulation of food intake via hypothalamic activity
(Satoh, H., et al., 2005). Yet, it has become clear that leptin functions in a different manner when
it comes to the direct regulation of glycemic levels (Muoio, D., Newgard, C. (2008). Leptin has
also shown peripheral insulin sensitizing properties in certain cases. Yet, leptin resistance, in
which the increasing levels of leptin witnessed in insulin resistant individuals exhibit a
diminished bodily response due to the greater than normal presence of the protein itself, hampers
the effectiveness of leptin as a supplementary compound (Muoio, D., Newgard, C., 2008).
The function of the adipokine omentin needs to be further elucidated, but it may enhance
the body’s response to insulin. A definite inverse correlation has been shown regarding omentin
levels in relation to obesity (Muoio, D., & Newgard, C., 2008). Yet, too little is known about the
function of omentin to state with any degree of certainty that supplementation of this adipokine
could resolve, at least temporarily, a state of insulin resistance.
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Resistin, while shrouded in controversy, has been hypothesized to be a link between
inflammatory mediators and metabolic modulators (Muoio, D., & Newgard, C., 2008). Showing
a direct correlation with adiposity and lipid levels in mouse models, resistin is a clear exclusion
from any sort of supplementary therapy to treat diabetes mellitus (Rajala, M. W., et al., 2004).
Elevated levels of retinol binding protein 4 (RBP4) have been presented in humans and
mice concurrently to obese and insulin resistant states. In fact, overexpression of RBP4 was
accompanied by insulin signaling impairment in mouse model studies (Muoio, D., & Newgard,
C., 2008). Thus, supplementation of RBP4 would not enhance insulin signaling. While the direct
correlation between retinol binding protein and negative metabolic complications remains clear,
further research needs to be performed to better elucidate the mechanisms and specific actions of
RBP4 (Muoio, D., & Newgard, C., 2008).
Tumor Necrosis Factor alpha concentrations are directly correlated with obesity. In fact,
deletion of TNF-alpha receptors improves insulin sensitivity in obese mice (Adamczak, M. et al.,
2004). It has been hypothesized that TNF-alpha overexpression blocks the action of insulin in the
body. This claim has been supported via the same mechanism in cultured cells (Adamczak, M. et
al., 2004).
Even with all that is known about adipokines, conflicting data and a lack of clarity
regarding their mechanisms justifies the need for more research into adipokines and their
interplay.
Inflammation
In-vivo studies in mice seem to show a relationship between insulin resistance and
chronic inflammation (Arkan, M., Hevener, A., Greten, F. et al., 2005). Mice with a
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constitutively functioning Inhibitor of Nuclear Factor Kappa B subunit beta (IKKβ), an activator
of the inflammatory mediator NF-kB (Liu, T., et al., 2017), developed glucose intolerance and a
state of insulin resistance (Arkan, M., Hevener, A., Greten, F. et al., 2005). In mice with IKKβ
knockout in hepatocytes, liver responsiveness to insulin was retained with a high fat diet (HFD),
but peripheral resistance to insulin was developed. With the deletion of IKKβ in myeloid cells,
systemic insulin sensitivity improved. As such, myeloid cells were suggested to be the mediator
of communication between insulin responsive tissues that utilize proinflammatory cytokines
(Arkan, M., Hevener, A., Greten, F. et al., 2005). Either way, it is clear from animal models that
inflammation pathways underlie and greatly affect insulin responsiveness.
Adiponectin
The most abundant protein secreted by adipose tissue, the signaling protein adiponectin
(ACRP30) is secreted primarily by white adipose cells (Rabe, K., Lehrke, M., Parhofer, K. G., &
Broedl, U. C. 2008, and Achari, A. E., & Jain, S. K., 2017). ACRP30 is also expressed by
osteoblasts, liver parenchyma cells, myocytes, and epithelial cells in comparatively low levels
(Achari, A. E., & Jain, S. K., 2017). The loci 3q27 is the responsible gene coding region for
ACRP30 (Khoramipour, K., 2021). From adipocytes, adiponectin can be secreted in three
different forms, a 67 kDa trimer, a 140 kDa hexamer, and a 300 kDa multimer also known as
high molecular weight adiponectin (HMW) (Achari, A. E., & Jain, S. K., 2017). This HMW
complex of adiponectin consists of a globular region, collagenous domain, species-specific
region, and signal peptide. The full-length form of adiponectin, along with its globular form
derived from proteolysis of the multimer, are the primarily vehicles for the protective effects of
adiponectin. (Palanivel, R., et al., 2007).
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Adiponectin has two major receptors, Adiponectin Receptor 1 (AdipoR1) and AdipoR2
(Yamauchi, T., et al., 2007). Both receptors are of similar structure with seven transmembrane
domains (Achari, A. E., & Jain, S. K., 2017). In addition, T-Cadherin has adiponectin binding
properties specifically for HMW adiponectin (Achari, A. E., & Jain, S. K., 2017). AdipoR1 is
expressed most prominently in skeletal myocytes and has a greater affinity for globular
adiponectin than its HMW multimer (Yamauchi, T., et al., 2007). In contrast, AdipoR2 is
expressed most concentrated in the liver with the preferred ligand of HMW ACRP30 (Yamauchi,
T., et al., 2007). As previously mentioned, adiponectin has been reported to have significant
insulin-sensitizing and anti-atherogenic properties in vivo mice (Okamoto, Y., et al, 2002). Thus,
research has been conducted to elucidate the intracellular signaling of adiponectin via its
receptors, AdipoR1 and AdipoR2. Adiponectin has been reported to activate AMP activated
protein kinase through the direct mediation of APPL1 (Achari, A. E., & Jain, S. K., 2017). AMP
activated kinase has been shown to contribute to the cell’s energy metabolism, including the
oxidation of hepatic cell fats in vivo through the action of Acetyl-CoA carboxylase (ACC) (Xu,
A., et al., 2003 and Foretz, et al., 2018). Adiponectin has also been shown to increase the
expression of peroxisome proliferator-activated receptor alpha (PPAR-α), a transcriptional factor
heavily involved with energy homeostasis and fatty acid oxidation (Achari, A. E., & Jain, S. K.,
2017). Adiponectin levels are inversely correlated with obesity and insulin resistance in animal
models (Rabe, K., Lehrke, M., Parhofer, K. G., & Broedl, U. C. (2008). Additionally,
adiponectin infusion increased glucose uptake, myocytic fat oxidation and decreased glucose
production in mice (Rabe, K., Lehrke, M., Parhofer, K. G., & Broedl, U. C. (2008). Considering
the implications of fatty acid accumulation in insulin resistance, it is plausible that ACRP30 has
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anti-diabetic properties.
Recently, it has become more evident that single nucleotide polymorphisms, specifically
a thymine in place of a guanine at the +276 locus in the adiponectin locus, may be associated
with increased body mass index (BMI) and type II diabetes, (Rabe, K., Lehrke, M., Parhofer, K.
G., & Broedl, U. C. (2008).
Adiponectin Action in Hepatocytes
It has been implied through in-vivo observations that at least part of the glucose lowering
abilities of adiponectin comes from its ability to decrease endogenous glucose production (EGP)
in the liver (Stefan, N., et al., 2003). This lowering of EGP was seen with a decrease in
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) activity,
both heavily involved in hepatic gluconeogenic activity. (Stefan, N., et al., 2003, and Zhang, X.,
et al., 2019). In addition, adiponectin has been pointed to as a potential amelioration of steatosis
in the liver. This action of reducing fatty content in hepatocytes is a result of modified acetylcoA-carboxylase (ACC) and fatty acid synthase activity (FAS). Both ACC and FAS are
important in fatty acid synthesis and oxidation (Xu, A., et al, 2003). In addition, ACRP30
supplementation has shown an increase in hepatic fatty acid oxidation through the modulation of
carnitine palmitoyltransferase 1 activity (Xu, A., et al, 2003).
Adiponectin Action in Skeletal Muscle
It has been demonstrated that adiponectin has a significant effect on glucose uptake and
fatty acid oxidation in skeletal muscle cells. Globular adiponectin has been shown to increase
glucose uptake in rat myocytes (Ceddia, R. B., et al., 2005). This increase in uptake is a
consequence of increased GLUT4 translocation (Ceddia, R. B., et al., 2005). Interestingly, in the
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same study, adiponectin decreased glycogen synthesis in muscle cells along with the increased
production of lactate (Ceddia, R. B., et al., 2005). Increased GLUT4 translocation has been
shown to be a product of ACRP30 induced activation of MAPK and AMPK pathways (Achari,
A. E., & Jain, S. K., 2017). Fatty acid oxidation, much like in the liver, is witnessed in skeletal
muscle cells because of AMPK activation (Achari, A. E., & Jain, S. K., 2017). In summation,
adiponectin has been shown to increase GLUT4 translocation, increase glucose uptake, and
increase fatty acid oxidation in the muscle cells of model organisms (Achari, A. E., & Jain, S. K.,
2017).
Physiological and pathophysiological concentrations of Adiponectin
Adiponectin levels have been shown to be significantly decreased in populations of
diabetic individuals in comparison to their non-diabetic counterparts. Levels of diabetic men
(6.6+/-0.4 μg/ml) were lower than non-diabetic males (7.9+/-0.5 μg/mL). A similar correlation
was seen in diabetic versus control women, 7.6+/-0.7 μg/mL and 11/7+/-1.0 μg/mL respectively.
This deficiency seen in the diabetic patients supports the notion that adiponectin supplementation
in diabetic patients may increase health outcomes (Hotta, K., et al., 2000). In addition, this
deficiency has been found to contribute to cardiovascular complications such as
macroangiopathy (Hotta, K., et al., 2000).
Existing Therapeutics for Type II Diabetes Mellitus
Insulin supplementation has prevailed as one of the most powerful treatment methods for
controlling hyperglycemia (Kharroubi, A. T., & Darwish, H. M. 2015). Insulin therapy has been
shown to be the most potent and cost-effective methodology regarding the treatment of diabetes
mellitus. Treatment with exogenous insulin early in the treatment of Type II Diabetes has been
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shown to lower glycemic levels and macrovascular risk (Kharroubi, A. T., & Darwish, H. M.
2015). While this method may be viewed with hesitancy, Weng et al. showcased the ability of
early, intensive insulin therapy to maintain and restore β-cell function (Weng, J., et al., 2008).
The incidence of hypoglycemic episodes of varying intensity are increased with the utilization of
insulin supplementation (Tomky, D., 2005). These hypoglycemic episodes, specifically in
patients with insulin dependent diabetes mellitus (IDDM) and NIDDM, have been linked to short
term deleterious effects and higher incidence of cardiovascular events (Kreider, K.E., et al.,
2017).
Metformin, a biguanide analog, is the most prescribed drug for the treatment of type II
diabetes (Horakova, O., et al., 2019). Metformin has been shown to reduce glucose levels in the
bloodstream via the suppression of glucose production in hepatocytes (Horakova, O., et al.,
2019). It has also been proposed that Metformin reduces hyperglycemia by inducing greater
glucose uptake in skeletal myocytes, yet this is not fully understood (Horakova, O., et al., 2019).
Metformin has proven to be an effective option for long-term glycemic control (Horakova, O., et
al., 2019).
Metformin was theorized to utilize adiponectin to exert its metabolic effects, yet recent
research has concluded that adiponectin is not involved in metformin’s insulin-sensitizing
activities (Fujita. H., et al., 2005). Metformin has shown the ability to reverse pancreatic beta cell
dysfunction due to chronic FFA exposure (Patanè, G., et al., 2000). Like adiponectin, metformin
has been shown to lower FFA levels (Patanè, G., et al., 2000). It is well understood that
metformin monotherapy is a relatively well tolerated approach resulting in good glycemic
control for human NIDDM patients (Defronzo, R. A., et al., 1995).
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Thiazolidinediones
Thiazolidinediones (TZDs), a drug class that acts as a PPAR gamma agonist, have been
utilized as a pharmacological treatment for diabetes (Achari, A. E., & Jain S. K., 2017). TZDs
have been shown to increase circulating adiponectin concentration (Achari, A. E., & Jain S. K.,
2017). As expected, TZDs, such as rosiglitazone, have been shown to increase insulin-sensitivity
via an uptick in serum adiponectin levels in obese mice alongside no improvement in insulin
sensitization in adiponectin-null mice (Kubota, N., et al., 2006). The proposed mechanism for
this increasing insulin sensitivity is through the acceleration of adiponectin production (Achari,
A. E., & Jain S. K., 2017). More specifically, TZDs lower blood sugar by increasing glucose
uptake and insulin sensitivity in skeletal muscle. This increase in adiponectin concentration, as
supported by prior studies, has also increased glucose tolerance and ameliorated hyperglycemia
(Achari, A. E., & Jain S. K., 2017). Unfortunately, thiazolidinediones have been linked to
increased fractures, cardiovascular events, edema, and weight gain from notable studies,
including one from the US Food and Drug Administration (FDA) (Lipscombe L. L., 2009). As a
result, the FDA has added a black box warning to TZD class drugs, including pioglitazone and
rosiglitazone (Achari, A. E., & Jain S. K., 2017).
Combination Therapeutics
While certain assays have proved effective alone, combination therapeutics may pose an
effective solution to better glycemic control. In a recent study conducted on Type II diabetic
youth, a combination of rosiglitazone and metformin lead to better long-term control of glycemic
levels in comparison to metformin alone (Today, 2007). In addition, treatment failure of the
combination group was significantly lower than either drug alone (Today, 2007).
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Geriatric Considerations
Almost half of individuals with type II diabetes are above the age of 60 (Adamczak, M. et
al., 2004). Therefore, therapeutic compounds should be well tolerated in the geriatric population.
With the possibility of complications higher in this population, hypoglycemic episodes should be
avoided in tandem with the consideration of liver and kidney function (Yakaryilmaz, F. D., and
Öztürk, Z. A. 2017). In fact, metformin usage is not recommended in geriatric cases with limited
kidney function (Adamczak, M. et al., 2004). In these cases, insulin therapy is often utilized with
frequent monitoring for hypoglycemia (Adamczak, M. et al., 2004). Yet, geriatric patients with a
glomerular filtration rate greater than sixty milliliters a minute are indicated for metformin use.
In fact, even with certain contraindications, metformin remains ever popular in the treatment of
geriatric type II diabetes mellitus (Yakaryilmaz, F. D., and Öztürk, Z. A. 2017).
Summary
Diabetes Mellitus is a public health crisis that shows no intention of slowing down
(Kharroubi, A. T., & Darwish, H. M., 2015). While multiple therapeutics exists, side effects are
prominent, and failure of glycemic control can still occur. Adiponectin, an adipocytokine,
(ACRP30) shows anti-atherogenic and insulin sensitizing properties in mice models. In addition,
adiponectin levels have been described as deficient across diabetic and obese patients, suggesting
potential benefits with the use of therapeutic supplementation. In the following meta-analysis,
the feasibility and efficacy of ACRP30 as a supplementary therapeutic for the treatment of Type
II diabetes mellitus will be explored.
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METHODS
A search for like-minded studies written between 2000 and 2021 was conducted using
PubMed and Google Scholar. The search terms for the effects of exogenous ACRP30 on insulin
resistance are as follows: “exogenous adiponectin” OR “exogenous adiponectin mice” OR
“adiponectin glucose tolerance” OR “adiponectin insulin resistance” OR “adiponectin
supplementation”. The search terms for the effects of Metformin on insulin resistance are as
follows: “Metformin glucose tolerance” OR “Metformin insulin resistance” OR “Metformin
mice insulin resistance”.
Out of all potential studies, inclusion required the fulfillment of the following
requirements showcased in Table 1.
Inclusion Criteria:
• Mouse Model
• Mice previously fed HFD or obese mice.
• Quantitative measurement of glucose tolerance test (table or graph)
• Quantitative measurement of fasting glucose of HFD or obese mice.
• Presence of Metformin usage or adiponectin supplementation in mice before fasting glucose
or GTT measurements.
• Quantitative presentation of HFD or obese control.
Table 1. Inclusion Criteria

Data Analysis
To elucidate the effects of adiponectin supplementation and metformin on insulin
resistant states in HFD or obese mice, area under the curve (AUC) measurements will be utilized
on GTT data to compare glycemic levels between the therapeutic and control group of each
study, then compared in a larger analysis to each other. This AUC measurement will elucidate
glycemic control in response to a glucose load such as at mealtime or in the presence of stressors.
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Fasting glucose and fasting insulin measurements will be compared across control and
therapeutic groups for both metformin and adiponectin.
The traditional trapezoidal method will be utilized to derive AUC values.
When available, direct data from tables will be utilized to conduct analyses. If not
available, WebPlotDigitzer will be utilized to extract data from available graphs. While, not as
accurate as directly presented numbers, data will be accurate enough to make general
observations on efficacy.
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RESULTS
Included Studies
As seen in Figure 1, included studies had to meet inclusion criteria while maintaining
similar environments between therapeutic and control groups. Dosing could not be kept constant.
This will be explored more in the discussion section. In addition, GTT values are all reasonable
but not controlled, see Table 2 below. The period in which fasting bloodwork was obtained was
somewhat variable. GTT findings were all performed after weeks of treatment.

Figure 1. Inclusion Review Process
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Author
Li et al., 2020

Therapeutic Group
Adiponectin (n=10)

Otabe et al., 2007

Adiponectin line 11
(n=6)
Adiponectin line 13
(n=6)
Adiponectin (n=6)

Otabe et al., 2007
Kandasamy et al., 2012

Koch et al., 2014
Kim et al., 2007

Adiponectin (n=9-11)
Control (n=9-11)
Adiponectin (n=5)
Control (n=5)

Values Tested
Fasting Glucose (FG),
Fasting Insulin (FI)
Fasting Glucose (FG),
Fasting Insulin (FI)
Fasting Glucose (FG),
Fasting Insulin (FI)
Fasting Glucose (FG),
Fasting Insulin (FI),
GTT (2g/kg)
GTT (1g/kg)

Findings
Therapeutic FG, FI
reduced from control
Therapeutic FG, FI
reduced from control
Therapeutic FG, FI
reduced from control
Therapeutic FG, FI, AUC
reduced from control
AUC reduced from
control
Therapeutic FG, FI, AUC
reduced from control

Matsui et al., 2010

Metformin .25% (n=7)
Control (n=7)

Matsui et al., 2010

Metformin .50%(n=7)
Control (n=7)

Horakova et al., 2019

Metformin 60 mg/kg
(n=4-5)

Fasting Glucose (FG),
Fasting Insulin (FI),
GTT (2.5g/kg)
Fasting Glucose (FG),
Fasting Insulin (FI),
GTT (2g/kg)
Fasting Glucose (FG),
Fasting Insulin (FI),
GTT (2g/kg)
Fasting Glucose (FG),
GTT (3g/kg)

Horakova et al., 2019

Metformin 200 mg/kg
(n=4-5)

Fasting Glucose (FG),
GTT (3g/kg)

Therapeutic FG, AUC
reduced from control

Horakova et al., 2019

Metformin 400 mg/kg
(n=4-5)

Fasting Glucose (FG),
GTT (3g/kg)

Therapeutic FG, AUC
reduced from control

Derkach et al., 2019

Metformin 200 mg/kg
(n=15)

Therapeutic FG, FI, AUC
reduced from control

Derkach et al., 2019

Metformin 400 mg/kg
(n=15)

Derkach et al., 2019

Metformin 600 mg/kg
(n=10)

Zhou et al., 2016

Metformin (n=4-6)

Zabielski et al., 2018

Metformin (n=8)

Fasting Glucose (FG),
Fasting Insulin (FI),
GTT (2g/kg)
Fasting Glucose (FG),
Fasting Insulin (FI),
GTT (2g/kg)
Fasting Glucose (FG),
Fasting Insulin (FI),
GTT (2g/kg)
Fasting Glucose (FG),
Fasting Insulin (FI),
GTT (1.5g/kg)
Fasting Glucose (FG),
GTT (3g/kg)

Table 2. Included Studies

26

Therapeutic FG, FI, AUC
reduced from control
Therapeutic FG, FI, AUC
reduced from control
Therapeutic FG, AUC
reduced from control,

Therapeutic FG, FI, AUC
reduced from control
Therapeutic FG, FI, AUC
reduced from control
Therapeutic FG, FI, AUC
reduced from control
Therapeutic FG, AUC
reduced from control

Adiponectin and Metformin effects on fasting glucose and insulin
Among analyzed groups of mice models, a 22% reduction of fasting blood glucose was
observed in mice experiencing long-term hyperadiponectinemia in comparison to high fat diet
controls. Fasting insulin in the same group comparison observed a 64% reduction. While fasting
glucose was consistently higher than normal diet mice without obesity, the reduction due to
adiponectin administration was significant. In analyzed groups of mice models administered with
various metformin dosages, a 14% reduction of fasting blood glucose was observed in
comparison to a high fat diet control. Similarly to the adiponectin group, a 30% reduction in
fasting insulin was witnessed.
Effects of Adiponectin and Metformin Administration on AUC for Glucose Tolerance Tests
Among collected glucose tolerance tests, a 41% reduction was witnessed in compiled
therapeutic groups from adiponectin. A 34% reduction was witnessed in groups with Metformin
administration.
For specific reductions in fasting glucose values, see Table 3. For specific reductions in
fasting insulin values, see Table 4. For specific reductions in GTT AUC values, see Table 5.
Compound/Dosage
Adiponectin 2.5 mcg/day
Adiponectin, transgene expression
Adiponectin, transgene expression
Adiponectin, transgene expression
Adiponectin, mouse plasmid DNA
Adiponectin, 1 mcg/day
Adiponectin, transgenic expression
Metformin .25% in HFD
Metformin .50% in HFD
Metformin 200 mg/kg
Metformin 400 mg/kg

Fasting Glucose Percent Reduction
15.87%
30.15%
20.59%
-5.10%
15.63
9.22%
67.94%
57.27%
59.09%
3%
13%
27

Metformin 600 mg/kg
Metformin 100 mg/kg
Metformin 300 mg/kg

19%
14%
20.57%

Table 3. Effects of adiponectin and metformin on reduction in fasting glucose values

Compound/Dosage
Adiponectin 2.5 mcg/day
Adiponectin, transgene expression
Adiponectin, transgene expression
Adiponectin, mouse plasmid DNA
Adiponectin, transgenic expression
Metformin .25% in HFD
Metformin .50% in HFD
Metformin 200 mg/kg
Metformin 400 mg/kg
Metformin 600 mg/kg
Metformin 100 mg/kg

Fasting Insulin Percent Reduction
70.71%
88.77%
39.30%
58.54%
70.32%
32.20%
21.54%
22.02%
19.27%
42.20%
43.35%

Table 4. Effects of adiponectin and metformin on reduction in fasting insulin values
Adiponectin, mouse plasmid DNA

49.79%

Adiponectin, 1 mcg/day

24.65%

Adiponectin, transgenic expression

56.76%

Adiponectin, 1 mcg

32.99%

Metformin, .25% in HFD

40.15%

Metformin, .5%

47.83%

Metformin, 60 mg/kg

16.63%

Metformin, 200 mg/kg

30.22%

Metformin, 400 mg/kg

45.23%

Metformin, 200 mg/kg

30.81%

Metformin, 400 mg/kg

31.05%

Metformin, 600 mg/kg

48.55%

Metformin, 100 mg/kg

33.69%

Metformin, 300 mg/kg

20.57%

Table 5. Effect of adiponectin and metformin on reduction in GTT AUC values
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70

65.53

Percent Decrease (%)

60
50
41.05
40
30

34.4738
30.11

26.6

22.04

20
10
0
1

2
Adiponectin

3

Metformin

Figure 2. Percent decrease of adiponectin (solid) and metformin (hatched), 1) fasting glucose 2) fasting insulin 3) glucose AUC
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DISCUSSION
Contextualizing the data, it is quite clear that adiponectin has significant glucose
homeostatic properties. Upon supplementation with ACRP30, whether upregulated genetically or
through injection, mice with supraphysiological concentrations of adiponectin had consistently
lower fasting glucose and fasting insulin values than their non-supplemented high fat diet control
counterparts.
With a 22.04 % reduction in fasting glucose among high fat diet mice when compared to
non-therapeutic controls, adiponectin has significant efficacy keeping glycemic concentrations
from reaching pathophysiological levels in insulin resistant and diabetic states. This efficacy
becomes quite clear when compared to the 26.6% reduction in fasting glucose in mice treated
with metformin.
Elucidating effect on fasting glucose alone is not enough to justify the therapeutic
potential of adiponectin. Utilizing the same organisms seen in the preceding values, a 65.53%
reduction in fasting insulin values was present in mice with adiponectin supplementation in
comparison to high fat diet controls. Considering these values were gathered simultaneously
across all analyzed data, a reduction in fasting glucose values in tandem with greatly reduced
plasma insulin values suggests that the body’s response to insulin has been greatly sensitized.
With a 22.04% reduction in fasting glucose and 65.53% reduction in fasting insulin, the insulin
sensitizing properties of the adipokine adiponectin seem to be significant in the basal state.
Yet, a physiological basal state is not constant for the human individual. Homeostatic
properties change in response to intake. Therefore, glucose tolerance tests were utilized to
illuminate adiponectin’s effectiveness at controlling blood sugar spikes in response to a bolus of
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glucose, such as in a high carbohydrate meal. Compared to a high fat diet control, mice with a
state of hyperadiponectinemia had an average area under the curve reduction of 41.05% in a twohour GTT. Therefore, supplementing with adiponectin to reach normal to excess levels to
combat ACRP30 deficiency was effective and significant at controlling near normal post-bolus
blood sugar levels.
In isolation, it is difficult to make clear the significance of these values. Metformin was
utilized as a standard of care (SOC) to help illustrate the potential anti-diabetic activities of
adiponectin against the most prescribed type II anti-diabetic drug.
On high fat diet mice under similar physiological conditions to that of the mice from the
adiponectin trials, a 26.6% reduction in blood glucose was witnessed as mentioned previously in
tandem with a 30.11% reduction in blood insulin values. It is quite clear that metformin has
significant anti-diabetic properties, effectively lowering basal blood sugar while also lowering
blood insulin values. To illustrate therapeutic metformin’s response to a sugar bolus, a two-hour
glucose tolerance test was utilized. Compared to control group high fat diet mice, metformin
treated mice had a 34.47% reduction in area under the curve value.
Comparatively, as seen in Figure 2, the mice in adiponectin trials experienced a lesser
reduction of fasting blood glucose and greater reduction of fasting blood insulin values than
metformin mice. Furthermore, adiponectin supplemented mice had a greater reduction in total
AUC values over control groups than the metformin trial mice.
This data in isolation supports the notion that insulin resistant mice experienced an
alleviation of this relative deficiency of insulin in response to an uptick of serum adiponectin
concentration whether it be from injection or overexpression of adiponectin. The extent of this
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amelioration performed similarly to the leading standard of care in this specific analysis.
It is quite clear that adiponectin is an effective anti-diabetic compound and should be
considered for further research regarding the adipokines therapeutic potential.
With the current mechanism of insulin resistance being mediated by fatty acid
accumulation in cells, it is feasible that adiponectin, a compound heavily involved in proper fatty
acid oxidation and glucose uptake, works in support of this theory.
Yet, further research is key. The potential of adiponectin’s efficacy is clear with varying
dosages of metformin as a benchmark. With the current proposed mechanism that adiponectin
both lowers EGP and increases peripheral tissues’ insulin sensitivity through the activation of
PPAR gamma pathways and ACC pathways, it is feasible that adiponectin supplementation
could competently control hyperglycemia.
While this data may make adiponectin seem like a stronger therapeutic candidate than
metformin, this data needs to be viewed with hesitancy. Considering the geriatric demand of type
II diabetes mellitus treatment, more research certainly needs to be done in geriatric models to
elucidate the relative efficacy of adiponectin in this demographic. Adiponectin supplementation
may not be a feasible therapeutic in old-age individuals due to the natural increase of adiponectin
with age. Comparatively, metformin is generally well tolerated, except in those with impaired
renal function (Yakaryilmaz, F. D., & Öztürk, Z. A., 2017).
Aside from geriatric treatment, dosing needs to be considered. Injection and even serum
concentrations of adiponectin can be easily measured. Yet, comparing dosing from adiponectin
to the standard of care metformin is quite difficult across research with many different dosage
measurements. Thus, conclusions to adiponectin’s effectiveness cannot be made until studies are
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completed with more standardized doses of adiponectin and metformin as well as more
standardized and controlled conditions. The prime example of the lack of control in this analysis
being the amount of treatment days allowed before test values were collected, as well as glucose
bolus quantities.
In fact, while this analysis strongly suggests that adiponectin has the potential to be a
therapeutic assay for the treatment of type II diabetes, it is infeasible to definitively say that it is
more effective than the SOC due to these dosing limitations. In addition, it is quite untested as to
what a long-term state of hyperadiponectinemia will do to the human organism as effects on
adipokine interplay are essential to consider. In addition, sex differences in human adiponectin
levels could change the perception of adiponectin’s effectiveness as physiological adiponectin
concentrations in females are varied from that of males.
In order to justify supplementary adiponectin as a potential therapeutic candidate to
ameliorate insulin resistance in the treatment of type II diabetes, far more standardized research
among model organisms need to be completed before human models can be considered. While
the potential is elucidated, dosing effectiveness and long-term viability, as well as geriatric
considerations, need to be considered far more seriously before any human supplementation or
therapy may begin.
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